OBLON
SPIVAK
McCLELLAND
MAIER
&
NEUSTADT
P.C.

ATTORNEYS AT LAW

Docket No.: _217408US0CONT_

ASSISTANT COMMISSIONER OF PATENTS
WASHINGTON, D.C. 20231

RE: Application Serial No.   10/022,874
        Applicant(s):   Chika NAKANISHI et al
        Filing Date: December 20, 2001
        For: DIHYDROPYRIDINE DERIVATIVES
   Attn: Application Division

SIR:

Attached hereto for filing are the following papers:

PRELIMINARY AMENDMENT
MARKED-UP COPY

Our check in the amount of $ __ is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Registration No. 24,618
Attorney of Record

Daniel J. Pereira, Ph.D.
Registration No. 45,518

22850

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :

CHIKA NAKANISHI ET AL : ATTN: APPLICATION DIVISION

SERIAL NO: 10/022,874 :

FILED: DECEMBER 20, 2001 :

FOR: DIHYDROPYRIDINE DERIVATIVES:

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as

follows:

IN THE SPECIFICATION

Please amend the specification as shown in the attached marked-up copy to read as

follows:

Please replace the paragraph at page 45, lines 19-22 with the following:

The title compound was obtained from 300 mg (0.97 mmol) of (3,3-diphenylpropane-

1-yl) 3-oxopentanoate, 150 mg (0.97 mmol) of 2-cyanoethyl 3-aminocrotonate and 109 μl

(0.97 mmol) of 3-chlorobenzaldehyde in the same manner as that of Example 1-1).

Please replace the paragraph at page 46, lines 12-13 with the following: